Medical devices, healthcare technology and the business of care
PMA approval · P200015

Edwards SAPIEN 3 Transcatheter Heart Valve System with Edwards Commander Delivery System

Edwards Lifesciences, LLC · Decision date Aug 31, 2020

MEDTECHLEDGER EXPLANATIONP200015

What did the FDA approve?

The FDA record P200015, decided August 31, 2020, covers the Edwards SAPIEN 3 Transcatheter Heart Valve System with the Edwards Commander Delivery System, a percutaneously delivered pulmonary valve prosthesis (product code NPV) from Edwards Lifesciences, LLC. The stated indication is management of pediatric and adult patients with a clinical indication for intervention on a dysfunctional right ventricular outflow tract conduit or surgical bioprosthetic valve in the pulmonic position, with greater than or equal to moderate regurgitation and/or a mean RVOT gradient of greater than or equal to 35 mmHg.

The supplied fields carry no supplement type or supplement reason and do not identify a prior PMA or a specific changed item. The identifier alone does not establish a supplement relationship, so the record is described only as an approval of the named system. The statement is the applicant's reported intended use; it does not by itself demonstrate safety or clinical effectiveness.

FDA approval order statement

Approval for the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System with Commander Delivery System is indicated for use in the management of pediatric and adult patients who have a clinical indication for intervention on a dysfunctional right ventricular outflow tract (RVOT) conduit or surgical bioprosthetic valve in the pulmonic position with greater than or equal to moderate regurgitation and/or a mean RVOT gradient of greater than or equal to 35 mmHg.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Aug 31, 2020

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P200015
Regulatory pathway
Premarket approval application
Product code
NPV
Decision code
APPR
Decision date
Aug 31, 2020
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Pulmonary valve prosthesis percutaneously delivered.

Product code
NPV
FDA device class
f

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P200015 received

    Application receipt date recorded by FDA.

  2. P200015 · FDA decision

    APPR

  3. P200015/S083 · Related supplement

    Edwards Crimper (9600LDS20, 9600LDS23, 9600LDS26, 9600LDS29)

  4. P200015/S077 · Related supplement

    SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra C Adaptive Prestent

  5. P200015/S084 · Related supplement

    Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX)

Timeline entries are records held by MedtechLedger for P200015. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200015

Explore the linked device profile

Other records with product code NPV

Product / regulatory recordCompanyPathwayDecision dateSource
Harmony TPV SystemP200046/S052
Medtronic, Inc.PMA supplementSep 30, 2026FDA
Medtronic, Inc.PMA approvalMar 26, 2021FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Edwards Lifesciences, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
One Edwards Way, Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records